Last reviewed · How we verify
Shirley Ryan AbilityLab — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
1 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Hydromorphone ER | Hydromorphone ER | marketed | Opioid analgesic | Mu-opioid receptor (μ-OR) | Pain Management | |
| Gralise | Gralise | marketed | Other |
Therapeutic area mix
- Oncology · 1
- Other · 1
- Pain Management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AdventHealth · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Ajay Wasan, MD, Msc · 1 shared drug class
- Alza Corporation, DE, USA · 1 shared drug class
- Archimedes Development Ltd · 1 shared drug class
- Asbjørn Mohr Drewes · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- AbbVie (prior sponsor, Abbott) · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shirley Ryan AbilityLab:
- Shirley Ryan AbilityLab pipeline updates — RSS
- Shirley Ryan AbilityLab pipeline updates — Atom
- Shirley Ryan AbilityLab pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shirley Ryan AbilityLab — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shirley-ryan-abilitylab. Accessed 2026-05-14.